ArticleFrontiers in immunology2026
Multi-epitope vaccine targeting SARS-CoV-2 omicron S and N proteins promotes enhanced immunity: a computational approach.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to the COVID-19 pandemic, which resulted in millions of deaths globally and had profound social, economic, and political consequences. Although effective vaccines and antiviral therapies have substantially reduced the global burden of COVID-19, the continued emergence of viral variants highlights the need for next-generation effective vaccine strategies capable of providing broader and more durable immune response. Methods: In this work, we provide an immunoinformatic approach for multi-epitope vaccine (MEV) design and prediction. Based on the spike (S) and nucleocapsid (N) proteins of SARS-CoV-2, immunoinformatic methods were used to identify the epitopes for B cells, cytotoxic T lymphocytes (CTL), and helper T lymphocytes (HTL). The B cell, CTL, and HTL epitopes were conjugated with flexible linkers GSG, GSGG, and a Gb-1 peptide conjugated to the C-terminal of the MEV ccandidate. Results: The final MEV candidate exhibited favorable predicted characteristics, with a molecular weight of approximately 55.47 kDa and a length of 498 amino acid residues. Computational analyses indicated that the designed construct was antigenic, non-toxic, non-allergenic, and possessed suitable physicochemical properties and predicted solubility, supporting its potential as a vaccine candidate for further investigation. Molecular docking analysis demonstrated favorable interactions between the MEV construct and selected Toll-like receptors (TLRs), while molecular dynamics (MD) simulations suggested the stability of the vaccine-receptor complexes throughout the simulation period. Furthermore, C-ImmSim-based immune simulation predicted the induction of both humoral and cellular immune responses following the proposed immunization schedule. Collectively, these findings highlight the potential of the designed MEV construct as a computationally optimized vaccine candidate and provide a framework for future experimental evaluation. Conclusion: This study presents a computationally designed MEV candidate against SARS-CoV-2 by integrating immunoinformatics approaches, structural modeling, molecular docking, molecular dynamics simulations, and immune response prediction. The findings suggest that the proposed MEV construct may possess favorable immunogenic and structural properties; however, experimental validation through
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.